presentations references investors investor overview press releases events & presentations financial information corporate governance stock information for further information our story our team board of directors join our team in the news contact us bringing hope and life changing therapies to patients & their families we develop therapies for patients with rare diseases learn more our lead candidate is a potential disease modifying therapy that may benefit all boys affected by duchenne muscular dystrophy regardless of their mutation type learn more join us in transforming science into life changing therapies learn more our story we are a team of experts from multiple disciplines who have come together driven to bring hope and life changing therapies to patients and their families . learn more october 11 2016 catabasis pharmaceuticals to present the movedmd trial of edasalonexent cat 1004 a potential disease modfying therapy for dmd at the american neurological association s 2016 annual meeting october 6 2016 catabasis pharmaceuticals presents positive data from part a of the movedmd trial of edasalonexent cat 1004 a potential disease modifying therapy for dmd at the world muscle society congress october 5 2016 catabasis pharmaceuticals announces promotion of andrew nichols ph.d. to chief scientific officer and angelika fretzen to senior vice president of product development patients & families we are honored and proud to be members of the duchenne muscular dystrophy dmd community one that is built on strength and determination . learn more science & technology each of our product candidates is created with our proprietary smart linker drug discovery platform to address a critical challenge in drug discovery the benefit of modulating multiple biological targets simultaneously to treat diseases successfully . learn more one kendall square bldg. 1400e suite b14202 cambridge ma 02139 617 349 1971 info catabasis.com one kendall square bldg. 1400e suite b14202 cambridge ma 02139 617 349 1971 info catabasis.com copyright 2016 all rights reserved terms of use privacy statement join our team contact us